FDA Peptide Reclassification 2026: BPC-157 and 13 Others Set to Return to Compounding Pharmacies

In a significant regulatory shift, HHS Secretary Robert F. Kennedy Jr. announced on February 27, 2026 that roughly 14 of the 19 peptides placed on the FDA's Category 2 restricted list — which had effectively barred compounding pharmacies from preparing them — would be reclassified to Category 1. This change would restore the ability of licensed compounding pharmacies to legally prepare these compounds under a physician's prescription. BPC-157, among the most widely researched and clinically used peptides for gut healing and musculoskeletal repair, is named in the expected returnees.

The practical implications are significant. For the past two years, prescribers who previously used compounded BPC-157 for conditions ranging from IBD to tendon injuries have been operating in a gray area, sourcing the compound through offshore channels or research-grade suppliers without clinical oversight. Category 1 status would not constitute FDA approval — these peptides remain unapproved drugs — but it would return them to the regulated compounding ecosystem with proper quality controls and physician-patient oversight.

Importantly, the formal reclassification process is still pending as of April 2026. The FDA has indicated it intends to convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026 to review BPC-157 and related substances. Until that review concludes, practitioners and patients should be aware that the legal status remains in transition. Full implementation of the broader reclassification is expected by mid-to-late 2026, and the peptide therapy community is watching closely.